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Abstract: Current research suggests that amygdalar volumes in patients with Alzheimer’s disease (AD) may be a relevant 
measure for its early diagnosis. However, findings are still inconclusive and controversial, partly because studies did not 
focus on the earliest stage of the disease. In this study, we measured amygdalar atrophy in 48 AD patients and 82 healthy 
controls (HC) by using a multi-atlas procedure, MAPER. Both hippocampal and amygdalar volumes, normalized by in-
tracranial volume, were significantly reduced in AD compared with HC. The volume loss in the two structures was of 
similar magnitude (~24%). Amygdalar volume loss in AD predicted memory impairment after we controlled for age, gen-
der, education, and, more important, hippocampal volume, indicating that memory decline correlates with amygdalar at-
rophy over and above hippocampal atrophy. Amygdalar volume may thus be as useful as hippocampal volume for the di-
agnosis of early AD. In addition, it could be an independent marker of cognitive decline. The role of the amygdala in AD 
should be reconsidered to guide further research and clinical practice. 
Keywords: Automatic segmentation, brain, hippocampus, MRI, neuropsychology. 
INTRODUCTION 
The neuropathology of Alzheimer’s disease (AD) is 
characterized by neuronal loss, first affecting the medial 
temporal lobe (MTL) [1, 2]. In particular, subregions of the 
hippocampus [3-6] and entorhinal cortex [7] undergo mas-
sive pathological changes, leading to progressive memory 
impairments [8-11]. Several studies suggest that hippocam-
pal atrophy is the best neuroimaging-derived marker of dis-
ease and disease progression. However, hippocampal atro-
phy is associated with a range of other neurological patholo-
gies [12-15], thus limiting its specificity to AD. With ad-
vances in automated volumetric segmentation, structures that 
were previously difficult to assess are now more reliably 
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segmented and evaluated. This has led to the discovery of 
other structures that undergo change in the course of demen-
tia, notably, other limbic structures close to the hippocam-
pus. In particular, the amygdala has recently received in-
creased attention. Tables 1 and 2 list studies that focus on 
amygdalar atrophy in mild to moderate AD (Table 1) and 
moderate to severe AD (Table 2), along with factors that 
influence (1) the magnitude of atrophy measured (i.e., par-
ticipants’ characteristics and segmentation procedures); and 
(2) the association with clinical features (i.e., information 
related to correlation analysis between cognitive scores and 
neuroanatomical volumes). Given our interest in amygdalar 
volume, we have included only those studies that consider 
data for this structure. Reduction of amygdalar volume com-
pared to elderly HC was a robust finding in post mortem 
studies [16-20] and in groups that included mildly and se-
verely affected AD patients compared with elderly HC, as 
shown in Tables 1 and 2 (Clinical Dementia Rating or CDR 
scores ranging from 0.5 to 3 [4]; Mini-Mental Score Exami-
nation or MMSE ranging from 5 to 21 [21]; MMSE ranging 
from 2 to 27 [22]; MMSE ranging from 11 to 25 [23]). This 
observation suggests that the diagnosis of AD may be im-
proved if amygdalar volume is considered in addition to hip-
pocampal volume [24]. However, findings are more contra-
dictory for earlier stages of the disease, such as AD patients 
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Table 1. Summary of research on amygdalar atrophy in mild to moderate AD. 
Disease 
Severity 
Population 
Characteristics 
Segmentation 
Characteristics 
Volume 
data 
Hippocampal 
Volume 
Amygdalar 
Volume 
Hippocampal 
vs.  
Amygdalar 
Atrophy 
Correlation 
Analysis of 
Volumes with 
Cognitive Score 
Regression  
Analysis of  
Volumes with 
Cognitive Score 
Reference 
Mild AD = 11; MMSE: HC 
= 29 (1); AD = 21.5 (5) 
Manual. MRI: 
1.5T - slice 
thickness: 5 mm 
ICV-
normalized 
volumes 
HC = AD (20% 
loss) 
HC > AD 
(33% loss) 
A > H AD; H and A: no 
significant corre-
lation with 
MMSE. AD + 
HC; A: correla-
tion MMSE 
 [31] 
Mild HC = 8; AD = 18. Age: 
HC = 69.2 (2.7); AD = 
72.4 (1.5); MMSE: HC 
= 28.7 (0.4); AD = 
22.3 (0.9; 13-27) 
Semi-automatic. 
MRI: 5 mm 
ICV-
normalized 
volumes 
HC > AD (30% 
loss) 
HC > AD 
(37% loss) 
A = H AD + HC; H: 
correlation MMSE, 
memory (Mattis, 
Wechsler, Grober 
Buschke Test, 
Verbal, Intrusion); 
A: no significant 
correlations 
 [25] 
Mild HC = 40; AD = 24. 
Age: HC = 79 (3.5); 
AD = 78.4 (3.2); 
MMSE: HC = 28.9 (1); 
AD = 22.1 (1.9) 
Manual. MRI: 
1.5T - slice 
thickness: 1.5 
mm 
ICV-
normalized 
volumes; 
age as 
covariate 
 HC > AD 
(18% loss) 
 AD + HC; A: 
correlation 
MMSE 
 [44] 
Mild HC = 7; AD = 8. Age: 
HC = 70; AD = 72; 
MMSE: AD = 23.9 
(17-29) 
Manual. MRI: 
1.5T - slice 
thickness: 1.5 
mm 
Raw vol-
umes  
HC > AD  HC = AD 
(p=0.06) 
A < H   [84] 
Mild HC = 21; AD = 13. 
Age: HC = 69.3 (6.8); 
AD = 71.2 (8.3); 
MMSE: HC = 29.7 
(0.2; 28-30); AD = 
23.7 (2.7; 20-28) 
Manual. MRI: 
1.5T et 0.5T - 
slice thickness: 
5 mm 
ICV-
normalized 
volumes; 
age as 
covariate 
HC > AD (19% 
loss) 
HC > AD 
(33% loss) 
   [32] 
Mild HC = 34; AD = 54. 
Age: HC = 72 (4); AD 
= 70 (8); MMSE: HC = 
28.4 (1.3); AD = 21.7 
(3.7) 
Manual. MRI: 
1.5T - slice 
thickness: 1.5 
mm 
ICV-
normalized 
volumes 
 HC > AD 
(21% loss) 
 AD; A: no sig-
nificant correla-
tion with MMSE 
 [45] 
Mild HC = 16; AD = 32. 
Age: HC = 70 (5); MA 
= 69 (8); MMSE: HC 
=28.6 (1.4); AD = 22.8 
(3.7)  
Manual. MRI: 
1.5T - slice 
thickness: 1.5 
mm 
ICV-
normalized 
volumes 
HC > AD (38% 
loss) 
HC = AD 
(16% loss) 
 AD; A: no signifi-
cant correlations 
(MMSE, verbal 
memory). H: 
correlation (MMSE, 
verbal memory)  
 [30] 
Mild HC = 94; AD = 118. 
Age: HC = 74 (5); AD 
= 75 (6); MMSE: HC = 
29 (1); AD = 21 (5) 
Automatic. 
MRI: 1.5T - 
slice thickness: 
1.3 mm 
ICV-
normalized 
volumes 
HC > AD HC > AD    [85] 
Mild HC 1 = 87; AD 1 = 90. 
HC 2 = 193; AD 2 = 
174. Age: HC 1= 77.7 
(7.9); AD 1 = 77.2 
(6.7); HC 2= 75.6 
(5.1); AD 2 = 75.5 
(7.3); MMSE: HC 1 = 
28.9 (1.2); AD 1 = 24.6 
(3.9); HC 2 = 29.1 (1); 
AD 2 = 23.3 (2) 
Automatic. 
MRI: 1.5T - 
slice thickness: 
1 mm 
Normalized 
volumes 
HC > AD 
(18.3% loss 
AD 1; 19.1% 
loss AD 2) 
HC > AD 
(19.3% loss 
AD 1; 
18.5% loss 
AD 2) 
A = H AD; H and A: 
correlation with 
MMSE and CDR 
AD 2; volumes, age, 
sex, education as 
covariates: H corre-
lations MMSE and 
CDR. A: no signifi-
cant correlations 
[26] 
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Disease 
Severity 
Population 
Characteristics 
Segmentation 
Characteristics 
Volume 
data 
Hippocampal 
Volume 
Amygdalar 
Volume 
Hippocampal 
vs.  
Amygdalar 
Atrophy 
Correlation 
Analysis of 
Volumes with 
Cognitive Score 
Regression  
Analysis of  
Volumes with 
Cognitive Score 
Reference 
Mild  HC = 19; AD = 20. 
Age: HC = 72.5 (7.8); 
AD = 72.7 (9.1); 
MMSE: HC = 29.1 (1); 
AD = 22 (4.3; 13-28) 
Manual. MRI: 
1T - slice thick-
ness: 1.3 mm 
Raw vol-
umes (spa-
tial normali-
zation on 
original 
images) 
HC > AD (26-
28% loss in 
right and left, 
respectively) 
HC > AD 
(19-24% 
loss in right 
and left, 
respectively) 
Right: A < H 
Left: A = H 
AD; H: no signifi-
cant correlation 
(language, visuo-
spatial, executive 
functions MMSE). 
A: correlation 
memory  
AD + HC; volumes 
and MMSE diagno-
sis as covariate: no 
significant correla-
tions 
[27] 
Mild HC = 20; AD = 20. 
Age: HC = 66 (6.7); 
AD = 70 (8.6); MMSE: 
HC = 27.6 (2.06); AD 
= 23.3 (2.56; 20-29) 
Manual. MRI: 
1.5T - slice 
thickness: 2 mm 
ICV-
normalized 
volumes 
HC > AD (30% 
loss) 
HC > AD 
(29.5% loss) 
A = H AD; H and A: 
correlation mem-
ory 
 [28] 
Mild to 
moderate 
HC = 15; AD = 12. 
Age: HC = 77 (10.6); 
AD = 78.4 (10); 
MMSE: AD = 20.8 
(3.7) 
Manual. MRI: 
1.5T - slice 
thickness: 1.5 
mm 
ICV-
normalized 
volumes for 
mid-sagittal 
intracranial area
 HC > AD    [86] 
Mild to 
moderate 
HC = 27; AD = 46; 
Age: HC = 71.1 (7.3); 
AD = 68.2 (7.9); 
MMSE: HC = 27.7 (2); 
3 groups: AD 1 (CDR 
0.5) MMSE = 23.2 
(3.7); AD 2 (CDR 1) 
MMSE = 20.2 (2.7); 
AD 3 (CDR 2-3) 
MMSE = 12.2 (3.4) 
Semi-automatic. 
MRI: 1.5T - 
slice thickness: 
1.5 mm 
ICV-
normalized 
volumes; 
age, sex, 
and educa-
tion as 
covariate 
HC = AD (CDR 
0,5); HC > AD 
(CDR 1; poste-
rior hippocam-
pus); HC > AD 
(CDR 1; anterior 
hippocampus) 
HC > AD (CDR 
2-3) 
HC > AD 
(CDR 0.5); 
HC > AD 
(CDR 1); 
HC > AD 
(CDR 2-3) 
  Volumes as covariate: 
AD (CDR 0, 5) + HC; 
A: correlations 
(verbal, visual, and 
Wechsler memory 
scores). AD (CDR 1) 
+ HC; A and H 
correlations (verbal, 
visual, and Wechsler 
memory scores) 
[4] 
Mild to 
moderate 
HC = 126; AD 1 = 36 
AD 2 = 43; AD 3 = 15. 
Age: HC = 71.1 (7.3); 
AD 1 = 72.9; AD 2 = 
73.5; AD 3 = 75.9. 
MMSE: HC = 28.6; 
AD 1 (CDR 0.5) = 
21.7; AD 2 (CDR 1) = 
18.9; AD 3 (CDR 2) = 
16 
Manual. MRI: 
1.5T - slice 
thickness: 1.6 
mm 
ICV-
normalized 
volumes, then 
W scores 
(normal 
deviates: 
percentiles 
relative to HC 
adjusted for 
age, gender, 
education, and 
duration of 
disease) 
    AD + HC; W scores 
volumes, age, sex, and 
education, diagnosis as 
covariates. H correla-
ion dementia scores 
Boston Naming Test, 
Wechsler, memory, 
verbal auditory learning
A: no significant 
correlations. AD; H: 
correlation Wechsler, 
verbal auditory learning
memory; A: no signifi-
cant correlations 
[10] 
Mild to 
moderate 
HC = 57; Mild = 66; 
Moderate = 79. Age: 
HC= 66.1 (8.3); Mild 
AD = 75.2 (7); Moder-
ate AD = 73.4 (8.6). 
MMSE: HC = 29 (28-
30); Mild AD = 23 (20-
25); Moderate AD = 19 
(16-22) 
Automatic. 
MRI: 1.5T - 
slice thickness: 
1.5 mm 
Raw vol-
umes - sex, 
education, 
and ICV as 
covariate 
HC > mild > 
moderate  
HC > mild = 
moderate  
  AD + HC; H and 
A: correlation 
(attention, lan-
guage, visuo-
spatial, memory, 
executive func-
tions, dementia 
scores) 
AD + HC: volumes, 
age, sex, education, 
and ICV as covari-
ate: H correlation 
(memory, visuo-
spatial, and execu-
tive functions, 
dementia scores). A: 
no significant corre-
lations  
[23] 
Note: Disease severity was coded as follows: Mean MMSE between 21 and 26: Mild. Mean MMSE between 13 and 20: Moderate. AD = HC means that volumes between both 
groups are equivalent. HC > AD means that volumes of HC are higher than AD patients. H: hippocampal volume, A: amygdalar volume, HC: healthy control individuals, AD: Alz-
heimer’s disease patients. 
 
with mild to moderate disease (see Table 1, MMSE scores 
ranging from 13 to 29 or CDR scores ranging from 0.5 to 1) 
[4, 10, 23, 25-28]. In particular, volume loss in mild to mod-
erate AD patients varies from 15-16% [29, 30] to 33-37% 
[25, 31, 32].  
The variation in findings may result from methodological 
issues related to amygdalar segmentation. Because of the 
numerous cortical and subcortical nuclei of the amygdala, its 
proximity to the hippocampus, and the similarity of neigh-
boring tissues, the boundaries of the amygdala are difficult
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Table 2. Summary of research on amygdalar atrophy in moderate to severe AD. 
Disease 
Severity 
Population Char-
acteristics 
Segmentation 
Characteristics 
Volume 
Data 
Hippocampal 
Volume 
Amygdalar 
Volume 
Hippocampal vs. 
Amygdalar 
Atrophy 
Correlation 
Analysis of 
Volumes with 
Cognitive Score 
Regression Analysis 
of Volumes with 
Cognitive Score 
Reference 
Moderate HC = 42;  
AD = 56. Age: HC 
= 73.2 (6.7);  
AD = 71.2 (8.6); 
MMSE: HC = 29 
(1); AD = 18.3 
(4.3) 
Manual. MRI: 
1.5T - slice 
thickness: 1.5 
mm 
ICV-
normalized 
volumes 
HC > AD (17% 
loss) 
HC > AD 
(23% loss) 
A = H AD; H: no corre-
lation (language, 
memory, orienta-
tion, praxis, 
MMSE). A: 
correlation 
(memory, orien-
tation, MMSE) 
 [37] 
Moderate HC = 10; AD = 
10. Age: HC = 56 
(11); AD = 57 (9); 
MMSE: HC = 29 
(1); AD = 15 (6) 
Manual. MRI: 
1.5T - slice 
thickness: 1.5 
mm 
ICV-
normalized 
volumes 
HC > AD 
(16.4% loss) 
HC > AD 
(15% loss) 
A = H   [29] 
Moderate HC = 19; AD = 
19. Age: HC = 
73.6 (5.5); AD = 
76.1 (5.7); MMSE: 
HC = 28.6 (1.1; 
27-30); AD = 13.1 
(3.8; 5-21) 
Manual. MRI: 3T 
- slice thickness: 
1 mm 
ICV-
normalized 
volumes; 
sex and 
education as 
covariate 
 HC > AD 
(22% loss) 
   [21] 
Moderate HC = 18; AD = 
27; Age: HC = 
69.5 (6.4); AD = 
71 (7.5); MMSE: 
HC = 30; AD = 19 
(3.6) 
Manual. MRI: 
1.5T - slice 
thickness: 1 mm 
ICV-
normalized 
volumes 
HC > AD (35% 
loss) 
HC > AD 
(16% loss) 
A < H AD; H and A: 
correlation 
MMSE 
 [38] 
Moderate HC = 126; AD = 
94. Age: HC = 79 
(6.73); AD = 73 
(8); MMSE: HC = 
28 (1.26); AD = 
17.8 (4.94) 
Manual. MRI: 
1.5T - slice 
thickness: 1.6 
mm 
Raw vol-
umes; ICV 
as covariate 
HC > AD HC > AD A < H   [3] 
Moderate HC = 22; AD = 
31; Age: HC = 
67.7 (7.9); AD = 
68 (6.8); MMSE: 
AD: 17.2 (3.2,14-
23); HC: 28.8 (1.1, 
25-30) 
Manual. MRI: 
0.5T - slice 
thickness: 5 mm 
Normalized 
volumes 
 HC > AD   AD; age and A 
volume as covariate: 
A: no significant 
correlation (MMSE, 
cognitive battery) 
[87] 
Moderate HC = 12; AD = 
46. Age: HC = 
66.2 (4.9); AD = 
70.3 (7.1); MMSE: 
HC = 28 (1); AD = 
19.6 (3.5; 12-26) 
Manual. MRI: 
1.5T - slice 
thickness: 1.5 
mm 
Normalized 
volumes 
HC > AD (15% 
loss) 
HC > AD 
(18.5% loss) 
 AD; H (right) and 
A: correlation 
(Wechsler visuo-
spatial memory). 
A: correlation 
(Wechsler verbal 
memory) 
AD; volumes, age, 
sex, and education as 
covariates: A corre-
lation (Wechsler 
visuo-spatial and 
verbal memory 
subset). H: no sig-
nificant correlation 
[5] 
Moderate HC = 27; AD = 
36. Age: HC = 72 
(4.2); AD = 73 
(8.9); MMSE: HC 
= 28; AD = 17.1 
(5.2; 2-27) 
Semi-automatic. 
MRI: 1.5T - slice 
thickness: 1.5 
mm 
ICV-
normalized 
volumes 
HC > AD (24% 
loss) 
HC > AD 
(21% loss) 
   [22] 
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Disease 
Severity 
Population Char-
acteristics 
Segmentation 
Characteristics 
Volume 
Data 
Hippocampal 
Volume 
Amygdalar 
Volume 
Hippocampal vs. 
Amygdalar 
Atrophy 
Correlation 
Analysis of 
Volumes with 
Cognitive Score 
Regression Analysis 
of Volumes with 
Cognitive Score 
Reference 
Moderate HC = 20; AD = 
20; MMSE: MA = 
18.8 (5.7; <26) 
Manual. MRI: 
1.5T - slice 
thickness: 2 mm 
ICV-
normalized 
volumes 
HC > AD (20% 
loss) 
HC > AD 
(33% loss) 
  AD; volumes, age as 
covariate: H no 
significant correla-
tion; A (Right) 
correlation (ADAS 
non-cognitive score); 
AD; cognitive scores, 
age as covariates: H 
correlation (ADAS 
non-cognitive score); 
A correlation 
(ADAS-non-
cognitive score, 
MMSE) 
[88] 
Moderate HC= 17; AD = 20. 
Age: HC = 63.6 
(10.5); AD = 63.8 
(9.1); MMSE: HC 
= 28.9 (1.3); AD = 
20.3 (5.1) 
Semi-automatic. 
MRI: 1.5T - slice 
thickness: 1.5 
mm 
ICV-
normalized 
volumes 
 HC > AD 
(20.5% loss) 
   [73] 
Moderate 
to severe 
HC = 57; Moder-
ate = 79; Severe = 
34. Age: HC= 66.1 
(8.3); Moderate 
AD = 73.4 (8.6); 
Severe AD = 71.3 
(9.6). MMSE: HC 
= 29 (28-30); 
Moderate AD = 19 
(16-22); Severe 
AD = 12.5 (11-18) 
Automatic. MRI: 
1.5T - slice 
thickness: 1.5 
mm 
Raw vol-
umes - sex, 
education, 
and ICV as 
covariate 
HC > moderate 
> severe 
HC > mod-
erate = 
severe 
 AD + HC; H and 
A: correlation 
(attention, lan-
guage, visuo-
spatial, memory, 
executive func-
tions, dementia 
scores) 
AD + HC: volumes, 
age, sex, education, 
and ICV as covari-
ate: H correlation 
(memory, visuo-
spatial, and executive 
functions, dementia 
scores). A: no sig-
nificant correlations 
[23] 
Note: Disease severity was coded as follows: Mean MMSE between 13 and 20: Moderate. Mean MMSE between 3 and 12: Severe. AD = HC means that volumes between both 
groups are equivalent. HC > AD means that volumes of HC are higher than AD patients. H: hippocampal volume, A: amygdalar volume, HC: healthy control individuals, AD: Alz-
heimer’s disease patients. 
 
to identify [33, 34]. Various approaches have been imple-
mented to assess MTL atrophy in AD. One of these is based 
on voxel-based morphometry, which investigates amygdala 
volume change in AD within the MTL [35, 36]. While this 
technique allows group comparisons between AD and HC, it 
cannot provide the absolute volume of the structure at the 
individual level. The second technique uses manual segmen-
tation of the amygdala on magnetic resonance imaging 
(MRI) [28, 31, 37, 38]. Although it remains the gold stan-
dard, this approach is impractical for cohorts beyond a cer-
tain size, because it requires a large amount of expert interac-
tion for each image [33]. The third technique consists of 
semi-automatic (18) or automatic segmentation of the 
amygdala and hippocampus [26] on the basis of single-
subject digital atlases. A limitation of these techniques is that 
single-subject atlases do not sufficiently take into account 
the neuroanatomical variation between subjects. This prob-
lem affects amygdala segmentation in particular, because the 
size and shape of the amygdala varies substantially even 
within demographically homogeneous groups of healthy 
subjects. This limitation can be addressed by probabilistic 
seeding followed by region-growing techniques [39] or by 
using multiple atlases [40, 41]. In combination with tissue 
probability maps to enhance registration, multi-atlas ap-
proaches are particularly suitable for subjects with neurode-
generative disease [42, 43]. We therefore used multi-atlas 
propagation with enhanced registration (MAPER) [42] to 
achieve the first objective of this study, which was to per-
form amygdalar volumetry in patients with mild to moderate 
AD. 
The relation between amygdalar atrophy and the severity 
of the disease is still a matter of debate (see Tables 1 and 2). 
A correlation between amygdalar atrophy and cognitive im-
pairment in AD has been found in some studies [5, 26, 27, 
37, 38], but not in others [25, 30, 31]. In most studies, the 
clinical significance of amygdalar atrophy in AD was esti-
mated without controlling for hippocampal atrophy [25, 30, 
31, 37, 38, 44, 45], which adds to the difficulty of interpret-
ing the results. Considering the strong functional connec-
tivity between the hippocampus and the amygdala, specifi-
cally in the context of memory [46, 47], it seems especially 
important to correct for hippocampal atrophy when assessing 
the specificity of the relationship between amygdalar atrophy 
and memory decline in AD. Furthermore, the majority of 
prior studies combined AD and HC groups for correlation 
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analysis [4, 10, 23], thus decreasing the sensitivity for detect-
ing changes of anatomical and functional correlations. Fi-
nally, some of these studies investigated the correlation be-
tween region volumes and global cognitive scores [26, 38] 
rather than measures of specific cognitive functions. The use 
of global cognitive scores reduces the sensitivity toward spe-
cific functional changes correlated with atrophy.  
In the present study, we used automated measurements of 
in vivo human brain volume obtained with MRI to evaluate 
amygdala and hippocampus volumes and investigated volu-
metric differences between AD patients and age-matched 
HC. To obtain automated segmentations of these structures, 
we used the MAPER approach, previously validated in neu-
rodegenerative disease [42, 43]. The procedure uses 30 train-
ing data sets (“atlases,” images with expert manual reference 
segmentations) [48, 49] to segment T1-weighted brain MR 
images. MAPER is the first automatic whole-brain multi-
region segmentation method that has been shown to yield 
robust results in subjects with neurodegenerative disease 
[43]. The accuracy achieved with such multi-atlas segmenta-
tions is approximately equivalent to that of manual segmen-
tation performed by trained operators (36). In addition, we 
aimed to explore how the neuropsychological test scores 
(assessing memory, language abilities, and executive func-
tions) correlate with either amygdala or hippocampus vol-
ume. Our goal was to assess whether amygdalar atrophy is a 
good predictor of early AD. Consequently, we aimed to as-
sess the linearity of the relationship between amygdalar vol-
ume and cognitive scores measured with clinical and neuro-
psychological tests. To determine the specificity of the rela-
tionship between amygdalar atrophy and cognitive functions, 
we performed multiple regression analysis, controlling for 
both demographic data and, more important, hippocampal 
volume. The main goal of this analysis was to determine 
whether amygdalar atrophy is a biomarker for AD independ-
ent of hippocampal atrophy. 
MATERIAL AND METHODS 
Participants 
We recruited patients with memory complaints who con-
sulted the Memory Center of the Grenoble University Hospi-
tal between October 2010 and February 2012. The diagnosis 
of probable AD was made according to the National Institute 
of Neurological, Communicative Disorders and Stroke and 
the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) criteria [50]. All patients were diag-
nosed after extensive clinical evaluation, including detailed 
history, physical and neurological examination, and exten-
sive neuropsychological tests. Only patients who were more 
than 60 years old (mean age of the AD group: 75.3 years; SD 
= 5.7) and who were new referrals for evaluation of memory 
complaints were included. Exclusion criteria were current or 
past diagnosis of somatic, psychiatric, or neurological disor-
ders such as stroke, head trauma, brain tumor, Parkinson’s 
disease, or temporal lobe epilepsy. In addition, subjects with 
findings suggesting another neurodegenerative disease, such 
as primary progressive aphasia, fronto-temporal dementia, 
Lewy body dementia, or mixed forms, were excluded. A 
total of 48 subjects were selected for our study (33 women 
and 15 men).  
Control subjects were selected from the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) database 
(www.loni.ucla.edu/ADNI)1. The inclusion criteria for nor-
mal subjects were as follows:  
1. No memory complaints aside from those common to 
other normal subjects of that age range  
2. Normal memory function documented by scoring above 
specific cutoffs on the Logical Memory II subscale (de-
layed paragraph recall) from the Wechsler Memory Scale 
– Revised2 (the maximum score is 25). The cutoffs were 
as follows:  
a. 9 or higher for 16 or more years of education  
b. 5 or higher for 8-15 years of education,  
c. 3 or higher for 0-7 years of education,  
3. MMSE score between 24 and 30 (inclusive) 
4. Clinical Dementia Rating and Memory Box scores of 
zero 
5. Absence of significant impairment of cognitive functions 
and activities of daily living 
6. Absence of depression (scores lower than 6 on Geriatric 
Depression Scale) 
Subjects were excluded if they were on current medica-
tion, except for vitamin E, estrogen, and estrogen-like com-
pounds if the dose had been stable for at least four weeks 
before screening. Eighty-two ADNI control subjects (mean 
age 76.2 years; SD = 5.1) were compared with the study 
group. Control subjects and patients did not differ in terms of 
age and gender composition. 
AD Neuropsychological Examination 
The neuropsychological examination of AD patients in-
cluded tests that were standardized for French native speak-
ers and that assessed (1) global cognitive functions (MMSE 
[51], French version [52]); (2) short-term memory (digit 
span forward and backward of the Wechsler Adult Intelli-
gence Scale [53]); (3) long-term memory (RL/RI16 [54], a 
word learning test based on the selective reminding proce-
dure developed by Grober and Buschke [55]; BEM 144 – 
figure learning, part of the Memory Performance Battery of 
the BEM-144 [56]; Doors and People Test [57]); (4) lan-
guage abilities (Famous Faces Test, an unpublished test de-

1 ADNI was launched in 2003 by the National Institute on Aging (NIA), the 
National Institute of Biomedical Imaging and Bioengineering (NIBIB), the 
Food and Drug Administration (FDA), private pharmaceutical companies 
and non-profit organizations, as a $60 million, 5-year public–private 
partnership. The Principal Investigator of this initiative is Michael W. 
Weiner, M.D., VA Medical Center and University of California San 
Francisco. ADNI is the result of efforts of many co-investigators from a 
broad range of academic institutions and private corporations, and subjects 
have been recruited from over 50 sites across the U.S. and Canada. The 
initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to participate 
in the research — approximately 200 cognitively normal older individuals to 
be followed for 3 years, 400 people with MCI to be followed for 3 years, 
and 200 people with early AD to be followed for 2 years. 
2 Modified from Wechsler D. Wechsler Memory Scale-Revised. San 
Antonio, Texas: Psychological Corporation; 1987. 
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signed to assess recognition and naming of 30 monochrome 
pictures of famous faces; Bachy-Langedock test, in which 
subjects have to name 36 black-and-white drawings of ordi-
nary objects; Irregular word writing, in which subjects have 
to write French words with unusual spelling); and (5) execu-
tive functions (Literal and category fluency – letter “p” and 
animals [58]; Trail making test, part A & B [59]). 
MRI Data Acquisition 
Atlas data as required for MAPER consisted of 30 T1-
weighted 3D image volumes acquired from healthy young 
adult volunteers at the National Society for Epilepsy at Chal-
font, United Kingdom at 1.5 T. Detailed demographics, ac-
quisition, and anatomical protocol information is available in 
Gousias et al., Hammers et al., and Niemann et al. [48, 49, 
60]. Hand-drawn segmentations of 83 structures had been 
prepared according to the protocols described in these re-
ports [48, 49, 60]. Segmentation protocols are also available 
at http://www.brain-development.org. We focused on four 
regions of interest, the left and right hippocampus, and the 
left and right amygdala. 
For the matched control subjects, we selected the ADNI 
1.5 T screening image and downloaded the pre-processed 
version (B1 non-uniformity correction, geometric distortion 
correction, bias field correction, and phantom scaling) as 
recommended by ADNI. The acquisition parameters for the 
various centers are available in Jack et al. [61]. 
MR images of patients were acquired on a 1.5 T Achieva 
MR scanner (Philips Healthcare) at Grenoble University 
Hospital, using a whole-body RF transmit coil and eight-
channel head receive coils. Anatomical studies consisted of a 
3D gradient recalled echo T1-weighted image (TR: 8.1 ms, 
TE: 3.8 ms, 1  1  1.3 mm voxel matrix, 256 mm field of 
view, 100 contiguous slices).  
Pre-Processing 
Additional pre-processing of MR images was carried out 
to determine the intracranial volume (ICV) and to obtain 
tissue-class probability maps. ICV masks were determined 
for the control group using the procedure described in 
Heckemann et al. [42]. As this procedure relies on a semi-
automatically generated white-and-grey matter mask, which 
was not available for the study group, we implemented [42] 
a multi-atlas label propagation procedure to generate ICV 
masks: a given study group (target) image was paired with 
each ADNI image and registered using non-rigid image reg-
istration. The resulting masks were added in the space of the 
target and thresholded at 50% to obtain an intracranial label 
for the target. The labels were visually reviewed for accu-
racy, and the threshold value modified to improve the ICV 
label if necessary. Probabilistic tissue-class maps were ob-
tained using FSL FAST [62]. 
Segmentation 
The MAPER procedure has been described and validated 
previously in AD populations [42, 43]. Each target is paired 
with each of the 30 atlases to generate an individual atlas-
based segmentation. This results in 30 segmentations for 
each target image, which are subsequently combined by us-
ing vote-rule decision fusion [41, 63]. 
Masking Based on Tissue Class 
We masked both regions (hippocampus and amygdala) 
by multiplication with a binary grey matter label generated 
as a maximum probability label with FSL FAST [62]. The 
analysis results reported in this work are based on the 
masked label sets. 
Visual and Statistical Analysis 
Masked hippocampal and amygdalar volumes in each 
target subject were visually checked by an expert (RAH; see 
example in Fig. 1). AD and HC were compared in terms of 
demographic and neuropsychological scores by using chi-
square tests (categorical variables) or Student’s t tests (con-
tinuous variables). Volumetric comparisons between groups 
were based on statistical analyses, including volumes nor-
malized by ICV. The normalized volume was calculated for 
each individual and each structure, and expressed as a frac-
tion of the total ICV, scaled by an arbitrary factor of 10
4
 
[(masked volume/ICV)  104]. Analysis of volumetric dif-
ferences between AD and HC groups (between-subject fac-
tor, the “Group” variable) was performed by using two 
within-subject factors: “Structure Volume” (ICV-normalized 
hippocampal and amygdalar volumes) and “Laterality” 
(right: R and left: L). Analysis of covariance (ANCOVA; 
General Linear Model [GLM]) was then used with ICV-
normalized volumes as a dependent variable; “Group”, 
“Structure Volume”, and “Laterality” as independent vari-
ables, and “age”, “gender”, and “education” as covariates. 
Since previous work revealed substantial differences in the 
magnitude of the amygdalar and hippocampal volume loss 
(see Tables 1 and 2), we additionally calculated an atrophy 
index for these structures, as follows: [1-(AD subject ICV-
normalized volume / HC mean ICV-normalized volume)] 
[26].  
To assess the relationship between AD patients' volumes 
and their cognitive scores (assessing memory, language 
abilities, and executive functions), we first analyzed whether 
the predictor variables (both hippocampal and amygdalar 
ICV-normalized volumes and age, sex, and education) were 
correlated with cognitive scores by using bivariate correla-
tions (Pearson’s r). Subsequently, we used multiple linear 
regressions to determine whether AD patients’ volumes pre-
dict cognitive scores (dependent variables), for each cogni-
tive score separately, considering the contribution of all pre-
dictor variables (i.e., age, gender, and education, as well as 
left and right hippocampal and amygdalar normalized vol-
umes, all as independent variables)
3
. Multiple linear regres-
sion analysis then takes into account each variable of interest 
in the same analysis, and so controls the influence of both 
neuroanatomical structures. 
RESULTS 
AD and HC groups did not differ significantly in age 
(AD range: 64-87; HC range: 65-87, t(1,128) = -0.92, p = 
3
 Multiple regression analysis without the contribution of the demographic 
data age, gender, and education was also tested; the significance of the 
predicted hippocampus and amygdala volumes on cognitive scores remained 
the same whether they were considered or not. To control for demographic 
modulation, we decided to keep this factor in the statistical analysis. 
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0.3), gender (2: 1.67, df = 1, p = 0.19), or total ICV (AD 
range: 1.2 – 1.6 l; HC range: 1.1 – 1.7
 
l, t(1,128) = -0.61, p = 
0.54). Compared with HC, patients had lower MMSE scores 
(AD range: 15-29; HC range: 26-30, t(1,128) = -14.5, p < 
0.001) and a lower level of education (t(1,128) = -10.6, p < 
0.001). MMSE scores of AD patients ranged from 15 to 29. 
Thirty-two patients (of 48) had mild AD severity (mean ± 
SD MMSE score 24.9 ± 2.3, range 21-29), and 16 of 48 had 
moderate AD severity (MMSE 18.1 ± 1.7, range 15-20). 
Subject characteristics are shown in Table 3. 
 
 
Fig. (1). Example of brain segmentations from a subject with AD. 
 
Table 3. Healthy control and AD patient group characteris-
tics. 
 HC (n=82) AD (n=48) 
Age (years; mean ± SD) 76.2 ± 5.1 75.3 ± 5.7 
Gender (W:M) 47 : 35 33 : 15 
Education (years; mean ± SD) 15.6 ± 3.2 8.1 ± 4.7 
MMSE (score; mean ± SD) 29.1 ± 0.9 22.6 ± 3.9 
ICV (L; mean ± SD) 1.36
 
± 1.2 1.35 ± 1.19 
Note. W = women, M = men, MMSE = Mini-Mental State Examination, ICV = total 
intracranial volume, n = number of subjects, SD = standard deviation, HC = healthy 
controls, AD = Alzheimer’s disease. 
Amygdalar and Hippocampal ICV-Normalized Volumes 
A significant main effect of Structure Volume (F(1,125) 
= 21.67; p < 0.001) and Group (F(1,125) = 131.7; p < 
0.001) was observed. Moreover, we observed a significant 
interaction of Structure Volume  Group (F(1,125) = 
16.01; p < 0.001). Planned comparisons demonstrated a 
significant effect of Group for the hippocampus (F(1,125) = 
93.4; p < 0.001) and the amygdala (F(1,125) = 113.3; p < 
0.001) (Fig. 2), indicating that, compared with HC, AD 
patients showed significantly smaller volumes of both hip-
pocampus and amygdala. The effect of age (F(1,125) = 
16.96; p < 0.001) and gender (F(1,125) = 5.41; p = 0.02) 
suggests that the amygdalar and hippocampal volumes de-
crease with age and are larger in women than in men. Edu-
cation level (F(1,125) = 1.33; p = 0.24) had no significant 
effect on structure volumes. 
 
Fig. (2). Box plot of the normalized hippocampal and amygdalar 
volumes in AD patients and HC. The center line shows the median, 
boxes capture the 25%-75% quantile range, and whiskers indicate 
1.5 interquartile ranges. The ring denotes an outlier. Normalized 
volumes represent gray-matter masked volumes in mm
3
, divided by 
total intracranial volume and scaled (arbitrarily) by 10
4
. AD = Alz-
heimer’s disease, HC = healthy controls. The volumes differed 
significantly between AD and HC subjects (p < 0.05). 
 
No main effect of Laterality (F(1,125) = 1.84; p = 0.17), 
Laterality  Group (AD patients’ right hemisphere volumes: 
mean ± SD 9.43 ± 2.84; AD patients’ left hemisphere vol-
umes: mean ± SD 8.95 ± 2.15; HC right hemisphere vol-
umes: mean ± SD 12.36 ± 3.09; HC left hemisphere vol-
umes: mean ± SD 11.85 ± 2.32; F (1,125) = 1.15; p = 0.69), 
and Structure Volume  Laterality  Group (F(1,128) = 0.56; 
p = 0.45) wasobserved in the full model (the physiological 
R>L asymmetry (e.g., [60]) was observed when age was 
removed from the model). For subsequent analyses, left and 
right volumes of each structure (i.e., hippocampus and 
amygdala) were averaged. 
To assess whether the magnitude of the atrophy was 
similar across structures in AD patients, we included the 
magnitude index of (R+L) hippocampal and (R+L) amygda-
lar volumes into the ANCOVA analysis, controlling for age, 
gender and education. Results revealed no significant effect 
of the magnitude of the volume loss (amygdalar volume loss: 
mean ± SD 25.4 ± 11.5 %; hippocampal volume loss mean ± 
SD 23.2 ± 14.2 %; F(1, 44) = 2.29; p = 0.13, representation 
as a percentage in Fig. 3). The volume loss for both struc-
tures was thus similar in AD patients. The effect of age (F(1, 
44) = 5.27; p=0.02) was statistically significant, but that of 
gender (F(1, 44) = 1.92; p = 0.17) or of education level (F(1, 
44) = 1.13; p = 0.71) was not. 
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Fig. (3). Magnitude of the reduction of hippocampal and amygdalar 
volume in AD patients relative to healthy controls. The center line 
shows the median, boxes capture the 25%-75% quantile range, and 
whiskers indicate 1.5 interquartile ranges. The ring denotes an out-
lier. The magnitude of atrophy is expressed as a percentage. 
Correlations Between ICV-Normalized Volumes and 
Neuropsychology Scores 
Bivariate correlations indicated that the ICV-normalized 
hippocampal and amygdalar volumes in AD patients were 
significantly and positively correlated. In addition, the ICV-
normalized hippocampal volume of AD patients was nega-
tively correlated with age (Table 4). MMSE scores were 
strongly correlated with gender and level of education, indi-
cating that higher MMSE scores were related to a higher 
level of education and that women had higher scores than 
men. Significant correlations were found between memory 
scores and amygdalar volume, whereas language abilities 
(naming of famous faces and irregular word writing tests) 
were correlated with hippocampal volume (Table 4). 
Multiple linear regression analysis (Table 5) was per-
formed to determine whether volumes in AD patients were 
predictive of cognitive decline. Age, gender, and education 
level were additionally included into the regression model as 
covariates. The amygdalar volume was correlated with 
memory performance (Grober & Buschke memory test) after 
we controlled for demographic variables and, of importance, 
after we controlled for hippocampal volume, indicating that 
amygdalar atrophy contributes to memory decline independ-
ently from hippocampal volume loss. Hippocampus or 
amygdala volumes did not predict scores for executive func-
tions. The amygdala volume was predictive of naming scores 
(Bachy-Langedock object naming test). 
DISCUSSION 
Hippocampal atrophy is considered the hallmark of AD. 
However, hippocampal volume loss is associated with many 
other diseases, including Parkinson’s disease [12], fronto-
temporal lobar degeneration [64], vascular dementia [13, 
14], and schizophrenia [15]. Moreover, researchers have 
detected substantial hippocampal volume loss in cognitively 
intact individuals [65]. Although hippocampal atrophy has 
strong sensitivity for AD, several studies showed that its 
specificity is low. To attempt to improve the identification of 
this disease by using neuroimaging markers, we evaluated 
the volume of two limbic structures, the hippocampus and 
the amygdala. We were also interested in evaluating the rela-
tionship between their volumes and neuropsychological test 
scores. 
A critical factor for sensitively in detecting the correla-
tions described in this work was the accuracy of the volume-
try method used. Manual image segmentation, while consid-
ered the gold standard, is impractical for studies of this size, 
and the quality of the segmentations depends on many meth-
odological details, e.g., slice thickness [33, 66, 67]. Conven-
tional automatic segmentation approaches frequently fail 
when the target image is affected by changes typical of neu-
rodegenerative disease, such as ventriculomegaly [43]. We 
used MAPER [42] and the largest single-investigator atlas 
database currently available, consisting of 30 manually seg-
mented atlases [48, 49]. This combination eliminates idio-
syncrasies typically associated with single-atlas methods and 
entails high accuracy as well as robustness toward atrophy-
related segmentation failures. MAPER has been extensively 
validated [42] and used [43] for target images acquired from 
patients with AD.  
Amygdalar atrophy was previously regarded as typical 
for moderate and late AD stages. We report here that it also 
occurs in early stages. The amount of volume loss is compa-
rable to that seen in the hippocampus. In addition, we ob-
served that amygdala volume predicts cognitive scores even 
after hippocampal volume is controlled for. This suggests 
that as a biomarker for early AD, amygdalar volume may be 
at least as important as hippocampal volume. 
A crucial question is whether regional atrophy predicts 
memory impairment. Contrary to recent findings [26, 37, 
38], our results have not revealed any significant correlation 
between a global index of clinical severity assessed with 
MMSE and the amygdalar and hippocampal volume. This 
may be due to the average MMSE score in our study being 
higher than in previous studies [37, 38]. For early disease, 
the MMSE scale may not be sensitive enough to reflect a 
relationship with atrophic regions [25, 31]. In addition, even 
when strong correlations between volumes and MMSE 
scores have been found [23, 26, 68] they did not remain sta-
tistically significant after factoring out other structure vol-
umes in a linear regression model. In this respect, our results 
are in agreement with other studies [25, 27, 30, 31, 45]. 
While significant correlations with MMSE were absent, 
more specific clinical indices of the disease, such as declara-
tive memory performance (Grober & Buschke test), did cor-
relate with amygdalar volume. Other authors have suggested 
that such a correlation is explained by the strong correlation 
between the amygdala and the hippocampus [46, 47]. We 
performed multiple regression analysis to evaluate amygda-
lar atrophy and cognitive scores independently of variations 
of hippocampal volume. We therefore posit that the 
amygdala has stronger relevance than previously acknowl-
edged. 
These results could also reflect an increased sensitivity 
owing to the accuracy of the MAPER method. Mori et al. [5] 
stressed that the correlation between hippocampal volume
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Table 4. Bivariate correlational analysis of the associations between predictor variables (demographic data and normalized volumes of 
the hippocampus and amygdala) and neuropsychological tests in patients with mild to moderate Alzheimer’s disease. 
Variables 1 – Age 2 – Sex 3 – Education 
4 – Normalized  
Hippocampus Volume 
5 – Normalized 
Amygdala Volume 
 Pearson's r 
1 – Age _ -0.14 0.30* -0.37** -0.25 
2 – Sex -0.14 _ -0.24 0.21 0.22 
3 – Education 0.30* -0.24 _ -0.18 0.03 
4 - Normalized hippocampus volume -0.37** 0.21 -0.18 _ 0.69** 
5 - Normalized amygdala volume -0.25 0.22 0.03 0.69** _ 
MMSE -0.04 -0.28* 0.49** -0.01 -0.08 
Memory      
WAIS : Digit span forward 0.16 -0.21 0.20 -0.22 -0.21 
WAIS : Digit span backward 0.10 -0.3 0.29 -0.27 -0.22 
RL-RI 16: Immediate recall 0.22 -0.25 -0.18 0.08 0.12 
RL-RI 16: Free recall 0.08 -0.03 -0.22 0.22 0.36* 
RL-RI 16: Total recall 0.03 0.10 -0.32 0.30 0.39* 
RL-RI 16: Delayed free recall 0.02 0.01 -0.26 0.28 0.44** 
RL-RI 16: Delayed total recall 0.10 -0.01 -0.34* 0.29 0.35* 
BEM 144: Immediate recall -0.18 -0.30 0.01 0.27 0.24 
BEM 144: Delayed recall -0.15 -0.32 0.00 0.28 0.33* 
Doors and People Tests (set A+ B) -0.31 -0.08 -0.12 0.25 0.09 
Language abilities      
Naming of famous faces 0.04 -0.02 0.02 0.50* 0.38 
Bachy-Langedock test 0.14 -0.04 0.15 -0.08 -0.03 
Irregular words writing 0.14 0.03 0.32 0.41* -0.23 
Executive functions      
VF: Literal 0.06 0.18 0.39* -0.10 0.09 
VF: Category -0.20 -0.09 0.11 0.20 0.20 
TMT: A 0.01 0.07 -0.18 0.17 0.26 
TMT: B 0.37* 0.03 -0.15 0.06 0.03 
Note: MMSE = Mini-Mental State Examination, WAIS = Wechsler Adult Intelligence Scale, RL-RI 16 = Rappel libre – Rappel Indicé of the Gröber & Buschke test, BEM 144 = 
Batterie d'Efficience Mnésique (Memory Performance Battery), VF = Verbal Fluency, TMT = Trail Making Test. Positive correlation for the sex variable means that females have 
higher scores than males. Negative correlation for the sex variable means that males have higher scores than females. Significant correlations are marked with asterisks: * p<0.05; ** 
p<0.01. 
 
and memory scores depends on whether the hippocampal 
segmentation encompassed the subiculum region. Critically, 
AD pathology affects numerous structures that surround the 
hippocampus, such as the subiculum, parahippocampal 
gyrus, and entorhinal cortex [69]. Anatomical connections 
between the subiculum and the hippocampus are particularly 
important in supporting memory functions [70]. Therefore, 
additional MTL structures not considered in our study (e.g., 
subiculum, entorhinal, perirhinal, or parahippocampal corti-
ces) may explain memory impairment beyond the hippo-
campus. Consistent with this possibility in this framework is 
that the hippocampus shows evidence for plasticity in de-
mentia. In fact, Dickerson et al. [71] demonstrated that com-
pensatory hippocampal mechanisms are activated during the 
earliest stages of the atrophy process. Moreover, Jin et al. 
[72] showed that neurogenesis in the hippocampus occurs 
even in the context of AD. Taken together, these studies 
support the view that correlations between hippocampal vol-
ume, hippocampal function, and memory impairment in AD 
are highly non-linear. 
 Overall, our results demonstrate that MAPER-based 
amygdalar volumetry can show major neuroanatomical
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Table 5. Multiple linear regression analyses of the associations between volumes of the hippocampus and amygdala and neuropsy-
chological tests in patients with mild to moderate Alzheimer’s disease. 
Neuropsychological Variable Hippocampus Amygdala 
 Mean SD Range * t Df p * t df P 
MMSE  22.6 3.9 (15-29) 0.06 0.29 42 0.77 -0.16 -0.88 42 0.38 
Memory            
WAIS : Digit span forward 5.3 0.9 (3-7) -0.08 -0.32 29 0.75 -0.09 -0.39 29 0.69 
WAIS : Digit span backward 4 4.1 0.7 (3-5) 0.03 0.13 22 0.89 -0.07 -0.34 22 0.73 
RL-RI 16: Immediate recall 
2
 13.4 2.2 (8-16) -0.32 -1.2 26 0.24 0.58 2.29 26 0.03* 
RL-RI 16: Free recall
 1,2
  11.4 6.9 (0-27) -0.28 -1.28 25 0.21 0.83 3.84 25 <0.01** 
RL-RI 16: Total recall  31.1 11 (3-48) -0.09 -0.39 29 0.69 0.63 2.92 29 <0.01** 
RL-RI 16: Delayed free recall 
1
  3.6 3.6 (0-12) -0.28 -1.39 29 0.17 0.86 4.27 29 <0.01** 
RL-RI 16: Delayed total recall  10.1 4 (1-16) -0.03 -0.17 29 0.86 0.59 2.82 29 <0.01** 
BEM 144: Immediate recall 
3
 5.2 2.1 (1.5-11) 0.1 0.46 29 0.65 0.08 0.36 29 0.71 
BEM 144: Delayed recall 
1, 3
  4.4 2.7 (0-10.5) 0.12 0.55 29 0.58 0.24 1.07 29 0.28 
Doors and People Tests (set A+ B) 
3
 12 5.3 (1-22) -0.02 -0.07 23 0.93 -0.03 -0.16 23 0.87 
Language abilities            
Naming of famous faces 55.9 23 (12-93) 0.49 1.64 17 0.11 0.18 0.57 17 0.57 
Bachy-Langedock test 1, 5  34.1 1.6 (30-36) -0.26 -0.99 23 0.33 0.74 2.82 23 0.01* 
Irregular words writing 
1, 5
 9.4 0.7 (8-10) 0.08 0.29 21 0.77 -0.44 -1.38 21 0.18 
Executive functions            
VF: Literal  17 6.4 (5-28) -0.16 -0.71 30 0.48 0.14 0.6 30 0.55 
VF: Category 
3
 16.8 5.9 (4-27) 0.05 0.19 29 0.85 0.08 0.33 29 0.74 
TMT: A 
1
 81.4 58.2 (26-310) -0.11 -0.47 30 0.63 0.36 1.49 30 0.14 
TMT: B 
1
 202.8 120.4 (62-538) 0.05 0.21 26 0.83 0.31 1.35 26 0.18 
Note: Cognitive tests were entered as dependent variables; hippocampal volumes, amygdalar volumes, age, sex, and education were entered as independent variables. MMSE = Mini-
Mental State Examination, WAIS = Wechsler Adult Intelligence Scale, RL-RI 16 = Rappel libre – Rappel Indicé of the Gröber & Buschke test, BEM 144 = Batterie d'Efficience 
Mnésique (Memory Performance Battery), VF = Verbal Fluency, TMT = Trail Making Test, SD = Standard Deviation, df = degrees of freedom. The reported mean, standard devia-
tion, and range were calculated after correcting for outliers (Stevens, 1984a). 1 The original data were transformed to the logarithmic function. 2 Two outliers on the Cook criterion 
were excluded. 3 One outlier on the Cook criterion was excluded. 4 Two outliers were excluded: one on the Cook criterion, one on the studentized residuals (SDR) criterion. 5 Three 
outliers were excluded on the SDR criterion. Significant associations are marked with asterisks: * p<0.05. ** p<0.01.  
a Stevens JP. Outliers and influential data points in regression analysis. Psychol Bull 95:334-44 (1984). 
 
differences between AD patients and HC. Amygdalar atro-
phy and its association with memory decline in the early 
stages of AD may be a useful marker for clinical diagnosis. 
However, additional studies are needed to assess in more 
detail the clinical relevance of investigating this structure. 
In particular, amygdalar atrophy patterns in AD could be 
compared with those occurring in other types of neurode-
generative disease. One study reported more severe 
amygdala atrophy in fronto-temporal dementia than in AD 
[73], but further work is needed to develop differential di-
agnostic criteria. Future studies should also investigate 
whether substantial amygdala volume change occurs in 
more cognitively intact persons, including patients with 
mild cognitive impairment (MCI). To clarify the potential 
role of the amygdala as an early AD biomarker, it may be 
relevant to assess whether the association between cogni-
tive abilities and amygdala volume in cognitively intact 
persons is dissimilar to that obtained in AD patients. In 
addition, correlations reported between amygdalar volume 
and cognitive scores are not proof of any mechanism of 
causation. The fact that the level of volume reduction in 
this structure can predict several types of cognitive decline, 
even after hippocampal volume is controlled for, may ap-
pear surprising, since the amygdala’s primary role is emo-
tion processing and not memory or language processing. 
However, the amygdala is intricately connected with the 
four lobes of the brain (i.e., occipital, temporal, parietal, 
frontal) [74], leading to its indirect implication in a vast 
range of cognitive functions, including perception, atten-
tion, and declarative memory [75]. Regarding memory 
function, the amygdala is able to modulate the encoding 
and consolidation of information when it pertains to emo-
tional stimuli [76-79]. In a recent functional MRI study on 
MCI and AD [80], authors found that functional connec-
tivity was notably decreased (according to disease severity) 
between the amygdala and structures of the default mode 
12    Current Alzheimer Research, 2014, Vol. 11, No. 2 Klein-Koerkamp et al. 
network (e.g., hippocampus, parahippocampal gyrus, supe-
rior frontal gyrus, medial frontal gyrus), an ensemble of 
regions implicated in an array of cognitive functions, nota-
bly episodic memory [80]. This decrease in functional con-
nectivity between the amygdala and structures of the de-
fault mode network is suggested to underlie the memory 
deficits observed in MCI and AD. Through its various con-
nections, the amygdala may have a role in modulating nu-
merous cognitive functions, including those that are af-
fected in dementia. Taken together, these studies show that 
the amygdala is not only an emotion-processing structure, 
but rather an essential part of a large network of structures 
that is able to adapt its activity as changes occur throughout 
the network. Further research is needed to assess the spe-
cific amygdalar compensatory mechanisms that take place 
throughout the course of dementia. If amygdalar volume 
loss is indeed predictive of cognitive decline and dementia, 
then affective disorders will most likely ensue, as the 
amygdala remains the key structure in processing emotions. 
Affective disorders have been previously observed in MCI 
and mild AD [81-83], yet whether these disturbances occur 
systematically and in parallel with amygdalar atrophy re-
mains unknown. 
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